by According to Precedence Research, during the forecast period of 2022 to 2030, the global asthma and COPD drugs market is estimated to develop at a compound annual growth rate (CAGR) of 5.4%. The global asthma and COPD drugs market was valued at USD 35.31 billion in 2021, and it is predicted to exceed USD 56.7 billion by 2030. The study investigates several elements and their consequences on the growth of the asthma and COPD drugs market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1711
This report focuses on asthma and COPD drugs market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall asthma and COPD drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of asthma and COPD drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of asthma and COPD drugs has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the asthma and COPD drugs market.
Some of the prominent players in the asthma and COPD drugs market include:
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co. Inc
- Grifols S.A.
- Novartis AG
- Cipla Inc.
- Abbott
- Astellas Pharma
- Hoffmann-La Roche Ltd
- Glenmark Pharmaceuticals
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1711
Segments Covered in the Report
By Diseases
- Asthma
- COPD
By Medication Class
- Combination Drugs
- Bronchodilators
- Inhaled Corticosteroids (ICS)
- Short Acting Beta Agonists (SABA)
- Long Acting Beta Agonists (LABA)
- Leukotriene Antagonists (LTA)
- Anticholinergics
- Anti-Inflammatories
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma and COPD Drugs Market
5.1. COVID-19 Landscape: Asthma and COPD Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma and COPD Drugs Market, By Diseases
8.1. Asthma and COPD Drugs Market, by Diseases Type, 2022-2030
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. COPD
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Asthma and COPD Drugs Market, By Medication Class
9.1. Asthma and COPD Drugs Market, by Medication Class, 2022-2030
9.1.1. Combination Drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bronchodilators
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhaled Corticosteroids (ICS)
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Short Acting Beta Agonists (SABA)
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Long Acting Beta Agonists (LABA)
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Leukotriene Antagonists (LTA)
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Anticholinergics
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Asthma and COPD Drugs Market, By Distribution Channel
10.1. Asthma and COPD Drugs Market, by Distribution Channel, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Drug Stores
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Asthma and COPD Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diseases (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Medication Class (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Teva Pharmaceutical Industries Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Grifols S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipla Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1711
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
